NasdaqGS:EXELBiotechs
Exelixis (EXEL) Margin Expansion To 35.1% Challenges Bearish Pricing Narratives
Exelixis (EXEL) opened 2026 with Q1 revenue of US$610.8 million and basic EPS of US$0.81, setting a clear marker for how the year is starting to shape up. The company has seen quarterly revenue move from US$555.4 million in Q1 2025 to US$610.8 million in Q1 2026, while basic EPS over that same span shifted from US$0.57 to US$0.81. This is prompting investors to focus on how sustained profitability and margins might influence sentiment around the latest numbers.
See our full analysis for...